Stock Track | Halozyme Therapeutics Plummets 9.72% Intraday on Unexpected Q4 Loss Driven by Acquisition Expenses

Stock Track

Feb 19

Halozyme Therapeutics' stock plummeted 9.72% during intraday trading on Wednesday, marking a significant decline for the biopharmaceutical company.

The sharp drop followed the company's report of an unexpected fourth-quarter loss, swinging to a loss of $141.6 million, or $1.20 per share, compared to a profit a year earlier. Analysts had expected earnings per share of $1.88. The loss was primarily driven by $284.9 million in acquired in-process research and development expenses related to Halozyme's acquisition of Surf Bio in December.

Despite the loss, revenue climbed 52% to $451.8 million, beating analyst estimates, and the company maintained its full-year outlook. CEO Helen Torley stated the Surf Bio acquisition broadens the company's drug delivery portfolio and diversifies long-term royalty revenue opportunities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1198503958"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198503958\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198503958?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 01:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198503958","market":"nz","top_or_hot":-1,"title":"Stock Track | Halozyme Therapeutics Plummets 9.72% Intraday on Unexpected Q4 Loss Driven by Acquisition Expenses","media":"Stock Track","content":"<p>Halozyme Therapeutics' stock plummeted 9.72% during intraday trading on Wednesday, marking a significant decline for the biopharmaceutical company.</p><p>The sharp drop followed the company's report of an unexpected fourth-quarter loss, swinging to a loss of $141.6 million, or $1.20 per share, compared to a profit a year earlier. Analysts had expected earnings per share of $1.88. The loss was primarily driven by $284.9 million in acquired in-process research and development expenses related to Halozyme's acquisition of Surf Bio in December.</p><p>Despite the loss, revenue climbed 52% to $451.8 million, beating analyst estimates, and the company maintained its full-year outlook. CEO Helen Torley stated the Surf Bio acquisition broadens the company's drug delivery portfolio and diversifies long-term royalty revenue opportunities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Halozyme Therapeutics Plummets 9.72% Intraday on Unexpected Q4 Loss Driven by Acquisition Expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Halozyme Therapeutics Plummets 9.72% Intraday on Unexpected Q4 Loss Driven by Acquisition Expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-19 01:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Halozyme Therapeutics' stock plummeted 9.72% during intraday trading on Wednesday, marking a significant decline for the biopharmaceutical company.</p><p>The sharp drop followed the company's report of an unexpected fourth-quarter loss, swinging to a loss of $141.6 million, or $1.20 per share, compared to a profit a year earlier. Analysts had expected earnings per share of $1.88. The loss was primarily driven by $284.9 million in acquired in-process research and development expenses related to Halozyme's acquisition of Surf Bio in December.</p><p>Despite the loss, revenue climbed 52% to $451.8 million, beating analyst estimates, and the company maintained its full-year outlook. CEO Helen Torley stated the Surf Bio acquisition broadens the company's drug delivery portfolio and diversifies long-term royalty revenue opportunities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1198503958","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198503958","pubTimestamp":1771434642,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Halozyme Therapeutics' stock plummeted 9.72% during intraday trading on Wednesday, marking a significant decline for the biopharmaceutical company.The sharp drop followed the company's report of an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"个股追踪|Halozyme Therapeutics盘中暴跌9.72%受收购费用推动Q4意外亏损","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"Halozyme Therapeutics' stock plummeted 9.72% during intraday trading on Wednesday, marking a significant decline for the biopharmaceutical company.The sharp drop followed the company's report of an unexpected fourth-quarter loss, swinging to a loss of $141.6 million, or $1.20 per share, compared to a profit a year earlier. Analysts had expected earnings per share of $1.88. The loss was primarily driven by $284.9 million in acquired in-process research and development expenses related to Halozyme's acquisition of Surf Bio in December.Despite the loss, revenue climbed 52% to $451.8 million, beating analyst estimates, and the company maintained its full-year outlook. CEO Helen Torley stated the Surf Bio acquisition broadens the company's drug delivery portfolio and diversifies long-term royalty revenue opportunities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}